Governance
The overall governance structure of MELISSA follows a multilayer structure that includes all partners grouped in the General Assembly, a Steering Committee, a Management Team, and the Coordinator. The management and governance structure ensures:
- support for individual partners for the achievement of project objectives,
- progress monitoring and control on work package level,
- coordination of project activities,
- implementation of quality control mechanisms by defining appropriate project standards,
- targeted dissemination of knowledge.
Coordinator
The Coordinator is the legal entity acting as the intermediary between all partners and the European Commission.
Management Team
The Management Team is the Consortium Body in charge of project management including monitoring and organisation.
Steering Committee
The Steering Committee is the supervisory body for the execution of MELISSA and oversees all work package activities assuring timely and high-quality attainment of all set objectives. I will be accountable and report to the General Assembly.
General Assembly
The General Assembly is the ultimate decision-making body of the consortium and includes at least one representative of all project partners.
Data Safety Monitoring Board
The Data Safety Monitoring Board is an independent committee which will oversee the clinical study and its outcomes, assess the progress of the clinical investigation at intervals, data safety or the critical clinical performance or effectiveness endpoints and to recommend to the sponsors whether to continue, suspend, modify, or stop the clinical investigation.
Scientific Advisory Board
The Scientific Advisory Board will integrate key industrial players and well acknowledged specialists in diabetology. They will advise the MELISSA team about the design of the clinical study, the design of the MELISSA applications and about the strategies linked to the dissemination and exploitation of the results of the MELISSA project.
external independent ethics advisor
An external independent ethics advisor with competence in AI systems will report to the European Commission on ethical issues that may arise in building the first automated AI-driven treatment personalisation and optimisation platform.
Patient Advisory Committee
The members of the Patient Advisory Committee will contribute their unique and invaluable perspectives and experiences to MELISSA.
Communication Committee
The Communication Committee plays a key role in guiding the external communication activities, including content development and quality assurance of all communication to specific target groups, such as patients, scientific community, healthcare professionals, regulatory bodies and the general public, among others.